Jonathan Metts
Expertise in
6
conditions

Dr. Jonathan Metts

Pediatric Hematology Oncology
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
Clinical Trials:Currently Recruiting for 5 Trials

Expertise in
6
conditions
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Metts specializes in pediatric hematology/oncology in the Johns Hopkins All Children's Cancer & Blood Disorders Institute. He sees patients on our main campus in St. Petersburg and at the Johns Hopkins All Children’s Outpatient Care Center in Tampa. He joined the hospital in 2016. He received his medical degree from the University of South Carolina School of Medicine and completed an internship and residency in pediatrics at Johns Hopkins All Children’s Hospital through the University of South Florida Morsani School of Medicine. Dr. Metts then trained at Emory University School of Medicine as a pediatric hematology/oncology fellow. His clinical interests include sarcomas, rare solid tumors, and Phase 1 and Phase 2 trials for pediatric solid tumors.

Dr. Metts is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Adult Soft Tissue Sarcoma.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Immune Thrombocytopenic Purpura (ITP).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in FL
Board Certifications
American Board Of Pediatrics
Fellowships
Emory University School of Medicine, Hematology/Oncology, DO, 2015
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Johns Hopkins All Children's Outpatient Care, St. Petersburg
601 5th Street South, Suite 320, Suite 320, Saint Petersburg, FL 33701
Call: 727-767-4176

Additional Areas of Focus

Dr. Metts has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


23 Clinical Trials

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Procedure, Other
Study Phase: Phase 3
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 11, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cyclophosphamide, Fludarabine, Melphalan, Tacrolimus
Study Phase: Phase 2
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Nirogacestat
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Nivolumab, Azacitidine
Study Phase: Phase 1
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
Enrollment Status: Suspended
Publish Date: October 31, 2025
Intervention Type: Biological, Procedure
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 2
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drug: Elimusertib
Study Phase: Phase 1/Phase 2
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Other
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
AflacST1603: a Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
AflacST1603: a Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 04, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 1
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: Seclidemstat, Cyclophosphamide, Topotecan
Study Phase: Phase 1
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Enrollment Status: Completed
Publish Date: October 26, 2023
Intervention Type: Other, Biological
Study Drugs: Dinutuximab, Sargramostim
Study Phase: Phase 2
View 18 Less Clinical Trials

35 Total Publications

A Phase I Trial of Nab-Paclitaxel in Combination With Gemcitabine for Relapsed/Refractory Pediatric Solid Tumors.
A Phase I Trial of Nab-Paclitaxel in Combination With Gemcitabine for Relapsed/Refractory Pediatric Solid Tumors.
Journal: Pediatric blood & cancer
Published: July 29, 2025
View All 35 Publications
Similar Doctors
Irmel A. Ayala
Experienced in Immune Thrombocytopenic Purpura (ITP)
Dr. Irmel A. Ayala
Pediatric Hematology Oncology
Experienced in Immune Thrombocytopenic Purpura (ITP)
Dr. Irmel A. Ayala
Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

601 5th Street South, Suite 700, Suite 7, Suite 700, Suite 7, 
Saint Petersburg, FL 
 (24.0 miles away)
727-767-8336
Languages Spoken:
English, Spanish
See accepted insurances

Dr. Ayala is the director of the Hemophilia and Bleeding Disorders Treatment Center at Johns Hopkins All Children's Hospital. She also is the hematology leader of the Young Women Bleeding Disorders/Menorrhagia Clinic, which focuses on a multidisciplinary approach to bleeding symptoms in girls and young women. Dr. Ayala also is involved in the Immune Dysregulation Clinic, which evaluates patients with autoimmune cytopenias in a multidisciplinary approach. Dr. Ayala joined the hospital in 2000. She was the chair of the Division of Hematology/Oncology between 2013-2017 and also served as interim director for the division between 2015-2016. Dr. Ayala's research experience includes multicenter national and international projects. Dr. Ayala received her medical degree from the University of Puerto Rico School of Medicine, her residency training at the San Juan City Hospital in Puerto Rico and her fellowship training at the Emory University School of Medicine Division of Pediatric Hematology/Oncology. Dr. Ayala is a member of the American Society of Pediatric Hematology/Oncology and the Hemophilia and Thrombosis Research Society. Dr. Ayala is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Hemophilia A, Venous Thromboembolism (VTE), Blood Clots, and Evans Syndrome.

Jennifer L. Mayer
Dr. Jennifer L. Mayer
Pediatric Hematology Oncology
Dr. Jennifer L. Mayer
Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
 (24.0 miles away)
727-767-4176
Languages Spoken:
English
See accepted insurances

Dr. Mayer is a pediatric hematologist-oncologist in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. She specializes in the diagnosis and management of patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Hodgkin lymphoma and non-Hodgkin lymphoma. She is also the medical director of the Vascular Anomalies and Birthmarks Program at the hospital. She cares for patients with benign and aggressive vascular tumors, lymphatic and venous malformations, and overgrowth syndromes. She was named the William A. Baumgartner Physician of the Year for Johns Hopkins All Children's in the 2024 Johns Hopkins Medicine Clinical Awards. She previously received the hospital’s Best Consulting Physician Award in 2017. Dr. Mayer is the author of more than 30 publications and two textbook chapters. She has presented over 22 research abstracts at national and international medical conferences. She is program director of a three-year fellowship training program in pediatric hematology-oncology on the St. Petersburg, Florida, campus. Dr. Mayer joined Johns Hopkins All Children’s in 1996. Dr. Mayer received her medical degree with honors from Dartmouth Medical School in New Hampshire. She completed her pediatric residency, hematology-oncology fellowship, and clinical research fellowship at Yale University School of Medicine in Connecticut. She is a fellow of the American Academy of Pediatrics and an active member and clinical researcher with Children’s Oncology Group, American Society of Pediatric Hematology-Oncology, and the International Society for the Study of Vascular Anomalies. Dr. Mayer is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Evans Syndrome, Acute Monoblastic Leukemia (AmoL), and Teratoma of the Mediastinum.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Colin Moore
Pediatric Hematology Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Colin Moore
Pediatric Hematology Oncology
601 5th St S, 3rd Floor, 
St Petersburg, FL 
 (24.7 miles away)
727-767-4176
Languages Spoken:
English
See accepted insurances

Colin Moore is a Pediatric Hematologist Oncology provider in St Petersburg, Florida. Dr. Moore is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Bannayan-Riley-Ruvalcaba Syndrome.

VIEW MORE IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Metts's expertise for a condition
ConditionClose
  • Elite
  • Ewing Sarcoma
    Dr. Metts is
    Elite
    . Learn about Ewing Sarcoma.
    See more Ewing Sarcoma experts
  • Osteosarcoma
    Dr. Metts is
    Elite
    . Learn about Osteosarcoma.
    See more Osteosarcoma experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Metts is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Rhabdomyosarcoma
    Dr. Metts is
    Distinguished
    . Learn about Rhabdomyosarcoma.
    See more Rhabdomyosarcoma experts
  • Advanced
  • Malignant Peripheral Nerve Sheath Tumor
    Dr. Metts is
    Advanced
    . Learn about Malignant Peripheral Nerve Sheath Tumor.
    See more Malignant Peripheral Nerve Sheath Tumor experts
  • Rhabdoid Tumor
    Dr. Metts is
    Advanced
    . Learn about Rhabdoid Tumor.
    See more Rhabdoid Tumor experts
  • Experienced
  • Childhood Acute Myeloid Leukemia
    Dr. Metts is
    Experienced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Denys-Drash Syndrome (DDS)
    Dr. Metts is
    Experienced
    . Learn about Denys-Drash Syndrome (DDS).
    See more Denys-Drash Syndrome (DDS) experts
  • Desmoplastic Small Round Cell Tumor
    Dr. Metts is
    Experienced
    . Learn about Desmoplastic Small Round Cell Tumor.
    See more Desmoplastic Small Round Cell Tumor experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Metts is
    Experienced
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Evans Syndrome
    Dr. Metts is
    Experienced
    . Learn about Evans Syndrome.
    See more Evans Syndrome experts
  • Hemophagocytic Lymphohistiocytosis
    Dr. Metts is
    Experienced
    . Learn about Hemophagocytic Lymphohistiocytosis.
    See more Hemophagocytic Lymphohistiocytosis experts
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.